Modern treatment of hyperkinetic disorders in children

The article is devoted to an important problem of pediatric neurology – hyperkinetic syndrome in children. It is widely known that hyperkinetic syndrome does not have nosological independence and is included in the structure of more than a hundred neurological diseases. The variety of these motor disorders includes a wide range of disorders from common motor tics to severe extrapyramidal disorders. In addition to the challenges of the diagnostic algorithm in verifying each clinical case, the most important task, to date, is the correction of these complex motor disorders.
During the treatment of these conditions, practical neurologists encounter polypharmacy, but even the simultaneous administration of several drugs does not lead to the desired effect. This fact has made it necessary to find new methods of treatment for these severe patients. Such a
scientific and practical search has led to the use of botulinum toxin type A in the correction of hyperkinetic syndrome.
In our article, using specific clinical examples, namely, severe congenital muscular dystonia and Hallervorden-Spatz disease which is a rare degenerative condition, we made an attempt to give an appropriate reasoning to the use of the botulinum toxin A drug Xeomin (Merz). It has been demonstrated that botulinotherapy in these patients not only enables to increase the motor volume, but also helps significantly reduce the amplitude and frequency of hyperkinetic manifestations, which positively affects the life quality of both the patients themselves and their families. It is known that botulinum toxin type A is widely practiced in the treatment of spastic forms of cerebral palsy in children and is the best pathogenetic cure for leveling high muscle tone. However, the application of botulinum therapy for severe hyperkinetic disorders in a number of cases is also the only appropriate therapeutic solution. The choice of the Xeomin drug can be explained by its safety, since this botulinum toxin type A has a high specific biological activity and the lowest content of complexing proteins.